Considering the frequency of an FGFR1/FGF overstimulation in many cancers, the hyper-inhibitory effect of this Spry4 version on FGFR1-expressing cells is a valuable insight that can be used for the development of therapeutic concepts, especially to combat cancers with this overexpression. This evidence concerns the gene FGFR1 and cancer.